Related Experiment Video
Updated: May 1, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Nucleoside analogs as anti-HBV agents
Xiao-Xiong Zhou1, Eddy Littler
1Department of Medicinal Chemistry, Medivir AB, Huddinge, Sweden. xiao-xiong.zhou@medivir.com
Abstract:
Chronic hepatitis B virus (HBV) infection affects about 400 million people worldwide. The development of nucleoside analogs that inhibit HBV polymerase provides an important approach for treating HBV infection. The approval of lamivudine, adefovir and entecavir represents a cornerstone of hepatitis B therapy. However, the challenges from the resistance and the off-therapy viral rebound are still unmet, and there is a need of developing new therapeutic agents. This review will discuss the structure-activity relationship of the most significant anti-HBV nucleoside analogs and the latest development in the field.
More Related Videos
05:55Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Retrovirus Life Cycles
Viruses with RNA Genomes
Subviral Agents
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction